BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 11509959)

  • 21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Induction of anti-tumour immunity by dendritic cells transduced with hTERT recombinant adenovirus in mice.
    Chen L; Tang XD; Yu ST; Ai ZH; Fang DC; Cai YG; Luo YH; Liang GP; Yang SM
    J Pathol; 2009 Apr; 217(5):685-92. PubMed ID: 19142972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide.
    Oh ST; Kim CH; Park MY; Won EH; Sohn HJ; Cho HI; Kang WK; Hong YK; Kim TG
    Vaccine; 2006 Apr; 24(15):2860-8. PubMed ID: 16443309
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors.
    Dullaers M; Van Meirvenne S; Heirman C; Straetman L; Bonehill A; Aerts JL; Thielemans K; Breckpot K
    Gene Ther; 2006 Apr; 13(7):630-40. PubMed ID: 16355115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma.
    Steitz J; Brück J; Lenz J; Knop J; Tüting T
    Cancer Res; 2001 Dec; 61(24):8643-6. PubMed ID: 11751377
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Engineering of highly immunogenic long-lived DC vaccines by antiapoptotic protein gene transfer to enhance cancer vaccine potency.
    Yoshikawa T; Niwa T; Mizuguchi H; Okada N; Nakagawa S
    Gene Ther; 2008 Oct; 15(19):1321-9. PubMed ID: 18480845
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mannan-modified adenovirus as a vaccine to induce antitumor immunity.
    Ding ZY; Wu Y; Luo Y; Su JM; Li Q; Zhang XW; Liu JY; He QM; Yang L; Tian L; Zhao X; Deng HX; Wen YJ; Li J; Kang B; Wei YQ
    Gene Ther; 2007 Apr; 14(8):657-63. PubMed ID: 17287861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injection of IL-12 gene-transduced dendritic cells into mouse liver tumor lesions activates both innate and acquired immunity.
    Tatsumi T; Takehara T; Yamaguchi S; Sasakawa A; Miyagi T; Jinushi M; Sakamori R; Kohga K; Uemura A; Ohkawa K; Storkus WJ; Hayashi N
    Gene Ther; 2007 Jun; 14(11):863-71. PubMed ID: 17344900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination.
    Chan T; Sami A; El-Gayed A; Guo X; Xiang J
    Gene Ther; 2006 Oct; 13(19):1391-402. PubMed ID: 16724093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction.
    Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A
    Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Immunization with dendritic cells infected with human AFP adenovirus vector effectively elicits immunity against mouse hepatocellular carcinomas].
    Tan XH; Zhu Q; Liu C; Liu XL; Shao XT; Wei B
    Zhonghua Zhong Liu Za Zhi; 2006 Jan; 28(1):13-6. PubMed ID: 16737612
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene transfer to dendritic cells induced a protective immunity against melanoma.
    Metharom P; Ellem KA; Wei MQ
    Cell Mol Immunol; 2005 Aug; 2(4):281-8. PubMed ID: 16274626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines.
    Ribas A; Amarnani SN; Buga GM; Butterfield LH; Dissette VB; McBride WH; Glaspy JA; Ignarro LJ; Economou JS
    Cancer Gene Ther; 2002 Nov; 9(11):875-83. PubMed ID: 12386826
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice.
    Sakai Y; Morrison BJ; Burke JD; Park JM; Terabe M; Janik JE; Forni G; Berzofsky JA; Morris JC
    Cancer Res; 2004 Nov; 64(21):8022-8. PubMed ID: 15520211
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhanced transduction of mouse bone marrow-derived dendritic cells by repetitive infection with self-complementary adeno-associated virus 6 combined with immunostimulatory ligands.
    Aldrich WA; Ren C; White AF; Zhou SZ; Kumar S; Jenkins CB; Shaw DR; Strong TV; Triozzi PL; Ponnazhagan S
    Gene Ther; 2006 Jan; 13(1):29-39. PubMed ID: 16136165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53.
    Nikitina EY; Chada S; Muro-Cacho C; Fang B; Zhang R; Roth JA; Gabrilovich DI
    Gene Ther; 2002 Mar; 9(5):345-52. PubMed ID: 11938454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.